Think Bioscience Secures $55M in Oversubscribed Series A Funding

Think Bioscience ("Think Bio"), a biotechnology firm dedicated to unlocking elusive drug targets, has successfully raised $55M in an oversubscribed Series A funding round. This round saw leadership from Regeneron Ventures, Innovation Endeavors, and Janus Henderson Investors, along with contributions from T.A. Springer, CE-Ventures, MBX Capital, and YK Bioventures. Returning investors include AV8 Ventures, CU Innovations, and Buff Gold Ventures.

The company focuses on creating small molecule drugs for historically challenging drug targets, employing synthetic biology to discover novel footholds for medicinal chemistry, such as protein pockets. Their lead program is aimed at addressing mutants that cause Noonan syndrome, a genetic disorder affecting roughly 1 in 2,500 births. Patients with Noonan syndrome experience severe cardiac and lymphatic issues, short stature, cognitive impairment, and chronic pain, among other symptoms, and currently, there are no approved therapies targeting the underlying biology of the condition.

"Our lead program has the potential to give a broad set of Noonan patients a better life," stated Dr. Jerome Fox, co-founder and CEO of Think Bioscience. "We are grateful to our investors for supporting our vision to develop life-changing therapies."

Despite advancements in computational chemistry, drug design remains a significant challenge. A large number of proteins within the human proteome are still deemed undruggable, as they lack obvious pockets for drug binding. Think Bio's synthetic biology platform harnesses high-throughput functional surveys to identify pockets that may be overlooked and utilizes them to further develop small molecules with biochemical activities that have previously been considered unachievable. Their platform has been successfully applied to a diverse range of targets, including transcription factors, protein phosphatases, kinases, proteases, and GTPases, while also building a robust internal pipeline.

"This team is succeeding where others have failed. The lead program is the best example, but just one of many that the company is prosecuting. We are enthusiastic to double down," remarked Nick Olsen, Partner at Innovation Endeavors.

About Think Bioscience: Think Bioscience is a privately held small molecule drug discovery company located in Boulder, Colorado. The organization is committed to developing therapeutics for targets that have traditionally been viewed as "undruggable." Their team combines expertise in synthetic biology, protein biophysics, applied enzymology, computational chemistry, and medicinal chemistry to launch first-in-class programs targeting diseases with significant unmet needs. Learn more at www.thinkbioscience.com.